Assessment of patient-reported outcome measures used in corneal transplantation: a systematic review

Long-term mental health outcomes after corneal transplantation and potential predictors: A multicentre prospective cohort study

INTRODUCTION

To evaluate the long-term effect of corneal transplantation on mental health outcomes and to assess potential predictors of these outcomes.

METHODS

For this multicentre prospective cohort study, patients awaiting corneal transplantation were recruited from 11 (academic) hospitals and eye clinics in the Netherlands. Participants (n = 238) completed the Centre for Epidemiological Studies Depression scale (CES-D), the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) and the Dutch ICF Activity Inventory Emotional Health subscale (DAI-EH) and Fatigue subscale (DAI-F) 1 month prior and 3, 6, 12 and 24 months after corneal transplantation. Sociodemographic and clinical characteristics, as well as coping styles as measured with the Utrecht Coping List, were considered as potential predictors for mental health outcomes (depression, anxiety, emotional health problems and fatigue). Linear mixed models were used to analyse and predict symptoms of depression, anxiety, emotional health problems and fatigue over time.

RESULTS

Scores on the CES-D and HADS-A improved significantly from baseline to 24-months (mean scores CES-D: 8.6 vs. 7.7, p = 0.03; mean scores HADS-A: 3.7 vs. 3.2, p = 0.002). Scores on the DAI-EH and DAI-F also improved significantly from baseline to 24-months (mean scores DAI-EH: 10.7 vs. 7.5, p < 0.001; mean scores DAI-F: 17.4 vs. 11.3, p < 0.001). Male sex and Fuchs' dystrophy were important predictors of better mental health outcomes, whereas comorbidity, (dry) eye complaints and a passive reacting coping style were important predictors of worse mental health outcomes.

CONCLUSION

Corneal transplantation had a positive impact on mental health outcomes and important predictors were identified. This study may improve the understanding of patients and eyecare practitioners about the effects of corneal transplantation, leading to realistic communication about corneal transplantation expectations.

Long-term outcomes of corneal transplantation: a review of 8,378 patients

PURPOSE

To analyze the outcomes of corneal transplantation procedures over a 13-year period at Farabi Eye Hospital, Tehran, Iran, to identify trends and determinants influencing the frequency and success of primary and re-transplantations.

METHODS

Utilizing a comprehensive dataset from the hospital's Hospital Information System, the study reviewed the records of 8,378 patients who underwent corneal transplants between 2009 and 2022. This analysis included demographic information, surgical details, and follow-up data. Statistical methods were applied to assess the impact of variables such as age, gender, surgeon experience, and surgical techniques on the likelihood of re-transplantation.

RESULTS

Of the 8,378 transplants, 7,660 (91.4%) were primary procedures while 718 (8.6%) involved re-transplantation. The most common primary transplant was penetrating keratoplasty (PKP, 50.3%), followed by Descemet's stripping endothelial keratoplasty (DSAEK, 29.3%), and deep anterior lamellar keratoplasty (DALK, 18.5%). Analysis revealed no significant association between re-transplantation rates and patient gender or nationality. Older recipient age correlates with higher re-transplantation rates, likely due to reduced regenerative capacity and increased comorbidities in older patients. Pre-transplant comorbidities (e.g., keratoconus, ulcers), concurrent surgeries (e.g., vitrectomy), and prior procedures (e.g., glaucoma surgeries, IOL implantation) significantly increase re-transplantation risk, likely due to additional ocular stress and inflammation.

CONCLUSION

The study highlights the importance of patient age, surgeon experience, and the choice of surgical technique in the success rates of corneal transplants. These factors are crucial for optimizing patient outcomes and minimizing the necessity for re-transplantations.

Nature of the evidence base and approaches to guide nutrition interventions for individuals: a position paper from the Academy of Nutrition Sciences

This Position Paper from the Academy of Nutrition Sciences is the third in a series which describe the nature of the scientific evidence and frameworks that underpin nutrition recommendations for health. This paper focuses on evidence which guides the application of dietary recommendations for individuals. In some situations, modified nutrient intake becomes essential to prevent deficiency, optimise development and health, or manage symptoms and disease progression. Disease and its treatment can also affect taste, appetite and ability to access and prepare foods, with associated financial impacts. Therefore, the practice of nutrition and dietetics must integrate and apply the sciences of food, nutrition, biology, physiology, behaviour, management, communication and society to achieve and maintain human health. Thus, there is huge complexity in delivering evidence-based nutrition interventions to individuals. This paper examines available frameworks for appraising the quality and certainty of nutrition research evidence, the development nutrition practice guidelines to support evidence implementation in practice and the influence of other sources of nutrition information and misinformation. The paper also considers major challenges in applying research evidence to an individual and suggests consensus recommendations to begin to address these challenges in the future. Our recommendations target three groups; those who deliver nutrition interventions to individuals, those funding, commissioning or undertaking research aimed at delivering evidence-based nutrition practice, and those disseminating nutritional information to individuals.

Real-World Experience in the Use of Immunosuppression for the Management of Inflammatory Eye Disease

PURPOSE

Patients with sight-threatening inflammatory eye disease (IED) are maintained on systemic immunosuppression whilst in long-term clinical remission. There are no clear guidelines on the duration of remission before implementing treatment withdrawal. We present a real-world analysis on the use of immunosuppression in IED in long-term remission and consider strategies for withdrawal.

METHODS

Adult IED patients on systemic immunosuppression were categorised into four disease groups: Corneal Transplant Survival Strategies (CTSS), Ocular Surface Disease (OSD), Non-infectious Uveitis (NIU) and Scleritis. Patients with Behçet's disease were excluded. Data on systemic immunosuppressants and biologics used; duration of treatment; reasons for drug discontinuation; disease activity/remission status; duration of clinical remission with an emphasis on patients who had been in remission for a minimum of 24 months were captured.

RESULTS

Out of a total of 303 IED patients, 128 were on systemic immunosuppression with a clinical remission of their ocular disease for ≥24 months. The median duration of remission was 4-5 years with the longest duration of remission 22 years, and some patients on immunosuppression for up to 23 years. Sixty patients stopped at least one immunosuppressive agent without prior discussion with a health-care practitioner.

CONCLUSION

Progressive conditions, such as cicatrising conjunctivitis may require lifelong immunosuppression, but patients with NIU and Scleritis and those on CTSS, immunosuppression withdrawal should be considered if they remain in remission for 2 years. Any patient stopping a medication should be contacted immediately for counselling. These data will better inform patients, encourage adherence and aide formal guideline development.